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ABSTRACT
Tamoxifen is an effective anti-estrogen treatment for patients with estrogen 
receptor-positive (ER+) breast cancer, however, tamoxifen resistance is frequently 
observed. To elucidate the underlying molecular mechanisms of tamoxifen resistance, 
we performed a systematic analysis of miRNA-mediated gene regulation in three 
clinically-relevant tamoxifen-resistant breast cancer cell lines (TamRs) compared 
to their parental tamoxifen-sensitive cell line. Alterations in the expression of 131 
miRNAs in tamoxifen-resistant vs. parental cell lines were identified, 22 of which 
were common to all TamRs using both sequencing and LNA-based quantitative 
PCR technologies. Although the target genes affected by the altered miRNA in the 
three TamRs differed, good agreement in terms of affected molecular pathways was 
observed. Moreover, we found evidence of miRNA-mediated regulation of ESR1, 
PGR1, FOXM1 and 14-3-3 family genes. Integrating the inferred miRNA-target 
relationships, we investigated the functional importance of 2 central genes, SNAI2 
and FYN, which showed increased expression in TamR cells, while their corresponding 
regulatory miRNA were downregulated. Using specific chemical inhibitors and siRNA-
mediated gene knockdown, we showed that both SNAI2 and FYN significantly affect 
the growth of TamR cell lines. Finally, we show that a combination of 2 miRNAs 
(miR-190b and miR-516a-5p) exhibiting altered expression in TamR cell lines were 
predictive of treatment outcome in a cohort of ER+ breast cancer patients receiving 
adjuvant tamoxifen mono-therapy. Our results provide new insight into the molecular 
mechanisms of tamoxifen resistance and may form the basis for future medical 
intervention for the large number of women with tamoxifen-resistant ER+ breast 
cancer.
                   Research Paper
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INTRODUCTION
Tamoxifen is a widely used therapy for estrogen 
receptor alpha-positive (ER+) breast cancer, and has been 
shown to be highly effective in the adjuvant setting, with 
28% reduction in mortality at 15 years of follow-up [1]. 
In addition to the adjuvant setting, anti-estrogen treatment 
with tamoxifen is also effective in the metastatic setting 
and, although not curative, extends survival. Tamoxifen is 
the recommended treatment modality for premenopausal 
breast cancer patients and for postmenopausal patients with 
contraindications for treatment with aromatase inhibitors 
(AIs). In addition, the side-effects of anti-estrogenic drugs 
differ and some patients may not be eligible for a given 
drug due to co-morbidities [2]. It is, therefore, rational to 
maintain tamoxifen as an adjuvant treatment option for 
postmenopausal ER+ breast cancer patients, although AIs 
have been shown to be superior in this group of patients 
[2]. Although tamoxifen greatly benefits many patients, 
recurrence occurs in almost all patients with advanced 
disease and approximately 30% of ER+ patients at 15-years 
of follow-up despite adequate treatment [1]. Metabolites of 
tamoxifen, such as 4-hydroxytamoxifen, bind to the estrogen 
receptor (ER), competing with estrogens and thereby 
inhibiting transcription of estrogen-responsive genes [3]. 
Previous studies have shown a loss or decreased expression 
of ER in ER+ breast cancer patients treated with tamoxifen 
[4, 5]. Altered ER expression might be linked to genetic and 
epigenetic changes, such as hypermethylation of CpG islands 
in 5’ regulatory regions of ER, or there may be other genetic 
events that affect ER expression [6]. For example, mutations 
localized in the ligand-binding domain of the ER gene 
(ESR1) have been identified in metastatic lesions of patients 
treated with tamoxifen [7, 8]. Various studies have shown 
the impact of altered expression of ER-beta, co-activators 
and co-repressors of ER, IGF1, IGF1R, IGFBP3 and various 
other growth factors and receptors on tamoxifen resistance 
[2, 5, 9, 10]. Aberrant activation of alternative pathways 
of cellular proliferation may also contribute to tamoxifen-
resistant tumor growth. Among the major players regulating 
molecular pathways are short, 21 nucleotide long, non-
coding genes called miRNAs that regulate gene expression 
at the post-transcriptional level. In mammals, more than 
60% of protein-coding genes undergo post-transcriptional 
regulation in the form of degradation or translation inhibition 
through miRNAs [11, 12]. Due to their potential to regulate 
mRNAs through tumor-suppressing or -inducing capacities, 
miRNAs have recently been investigated to determine their 
contributions to cancer development and progression [12, 
13]. Gene regulation by miRNAs often leads to activation 
or dysregulation of various pathways responsible for the 
development of drug resistance. For example, the miR-
221/222 cluster miRNAs regulate levels of ER and could 
thereby play a critical role in tamoxifen resistance and in 
ER+ cancers in general [14, 15]. Furthermore, a recent study 
has shown that miR-22 negatively regulates ER expression 
[16]. Apart from ER, restoration of TIMP3 expression 
via suppression of its regulatory miRNA (miR-222, miR-
181b) has been shown to restore tamoxifen sensitivity in a 
mouse tamoxifen-resistant xenograft model [17]. However, 
a majority of previous studies have focused on a limited 
number of miRNAs and have lacked a system-wide view of 
miRNA-mediated tamoxifen resistance.
In the present study, we investigated miRNA-
mediated gene regulation associated with tamoxifen 
resistance by analyzing a clinically-relevant, isogenic, 
human breast cancer MCF-7-based tamoxifen-resistant 
cell line model using small-RNAseq, global LNA-based 
miRNA quantitative RT-PCR (qPCR) and microarray 
profiling. Since it is known that miRNA target predictions 
often suffer a high number of false-positives, we performed 
integrative inverse-correlation analysis of miRNAs and 
mRNA expression profiles to distinguish likely functional 
miRNA-target relationships from spurious computational 
target predictions. The results provide interesting insights 
into affected biological processes in tamoxifen resistance. 
By integrating various lines of evidence related to miRNA-
gene regulation, we posit a novel functional miRNA-gene 
relationship, and a subsequent clinical validation confirmed 
that some of the miRNA alterations observed in our TamR 
cell line model correlated with disease outcome in clinical 
primary tumor samples of breast cancer patients receiving 
adjuvant tamoxifen mono-therapy.
RESULTS
Tamoxifen resistance-associated miRNA 
alterations in the tamoxifen-resistant cell line 
model
miRNA expression profiles of three tamoxifen-
resistant breast cancer cell lines (TamR1, TamR4 and 
TamR8) and the parental tamoxifen-sensitive cell line 
(MCF-7/S0.5) were analyzed by LNA-based qPCR in 
biological triplicates. Additionally, miRNA expression 
profiles for the 4 cell lines were obtained using Illumina’s 
small-RNAseq. Comparison of miRNA expression 
profiles of the 3 TamRs vs. MCF-7/S0.5 obtained 
by qPCR identified a common tamoxifen resistance-
associated signature consisting of 14 upregulated and 
8 downregulated miRNAs (Table 1 and Figure 1A). 
Moreover, each of the resistant cell lines exhibited altered 
expression of a large number of miRNAs compared to 
MCF-7/S0.5 (Supplementary Tables 1 and 2). In total, 131 
miRNAs exhibited alterations in expression between the 
parental and tamoxifen-resistant cell lines.
TamR1 and TamR4 shared 13 miRNAs expressed 
at significantly lower levels than MCF-7/S0.5, including 
an oncomiR miR-95. TamR1 and TamR8 shared 16, 
and TamR4 and TamR8 shared 19, miRNAs at lower 
expression levels than MCF-7/S0.5. In terms of miRNAs 
exhibiting higher expression in TamRs vs. MCF-7/
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S0.5 cells, TamR1 and TamR4 shared 22 miRNAs; 
TamR1 and TamR8 shared 21 miRNAs, including the 
tumor suppressors miR-181b, oncomiR miR-210 and a 
known ER regulator miR-18a [18]; and finally, TamR4 
and TamR8 shared 20 upregulated miRNAs, including 
oncomiRs miR-210, miR-203, miR-18a* (Figure 1A and 
Supplementary Table 1).
Expression levels measured by qPCR and small-
RNAseq showed a good overall correlation (Pearson’s 
correlation coefficient, 0.72) between mean Cp-value 
across cell line replicates and read counts for all cell 
line types (Figure 2A). A majority of differentially-
expressed miRNAs found by qPCR were also detectable 
using sequencing (Supplementary Table 3), and showed 
agreement in terms of the direction of expression change. 
Only a minority of differentially expressed miRNAs using 
qPCR were not detectable by small-RNAseq. Twenty-
eight of the 69 miRNAs exhibiting altered expression 
in TamR1 by qPCR showed altered expression profiles 
(absolute log 2-fold change of at least 0.7 in TamR1) by 
small-RNAseq. Similarly, 58 of the 103 altered miRNAs 
in TamR4, and 34 of 95 altered miRNAs in TamR8, also 
exhibited altered expression as determined by small-
RNAseq (Figure 2B and Supplementary Tables 3 and 
4). Pairwise comparisons of miRNA log2-fold changes 
for each TamR cell line measured by both technologies 
showed poor (r = 0.36 for TamR8) to good (r = 0.66 for 
TamR4) correlations (Figure 2C).
Global analysis of miRNA-target relationships
To analyze miRNA-mediated regulation in 
tamoxifen resistance, the expression profiles of 197 
miRNAs that exhibited ≥0.7 absolute log2-fold change 
by qPCR were integrated with global mRNA expression 
profiles of these same cell lines (Figure 3). Using inverse-
correlation analysis on miRNA-mRNA expression 
profiles, we derived miRNA-target pairs that, in addition 
to being predicted targets, showed inverse-correlation of 
miRNA-mRNA levels. Predicted miRNA targets with 
Table 1: Log-fold changes of miRNAs with consistent significantly altered expression across all TamR cell lines 
relative to MCF-7/S0.5 cell lines (adjusted P < 0.05) using LNA-based qPCR assay
miRNA TAMR1 TAMR4 TAMR8
miR-101* -1.02 -3.05 -1.37
miR-1201 -0.94 -1.36 -1.27
miR-1248 -1.68 -1.61 -1.01
miR-652 -1.99 -1.17 -1.64
miR-95 -1.82 -2.45 -1.19
miR-135b -1.89 -2.16 -2.33
miR-196a -1.54 -0.71 -1.65
miR-135a -2.84 -6.16 -4.74
miR-130b 0.75 0.94 0.89
miR-130b* 1.06 1.55 0.88
miR-152 1.29 1.4 1.49
miR-181b 0.89 1.14 0.95
miR-203 2.2 1.34 1.12
miR-210 0.7 1.18 1.49
miR-22* 0.97 0.88 0.82
miR-339-5p 1 1.26 0.8
miR-516a-5p 3.47 2.87 2.46
miR-517c 2.06 1.66 1.06
miR-519a 2.23 1.69 1.2
miR-519e 1.98 1.15 0.97
miR-551b 2.09 5.79 3.51
miR-582-5p 2.43 0.86 1.93
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Figure 2: Expression of miRNAs in tamoxifen-resistant and -sensitive cell lines. A. Global mean expression of miRNAs 
measured using qPCR and sequencing technologies showed a high overall correlation (r = 0.72). B. Agreement between significantly 
differentially-expressed (DE) miRNAs identified by qPCR vs. RNAseq. The number of up- and downregulated miRNAs discovered by 
both technologies are shown. C. Pearson’s correlation coefficients of miRNA fold-changes as measured by qPCR and sequencing platforms. 
The comparison is based on the set of miRNAs with significant differential expression using qPCR.
Figure 1: Inverse correlation analysis identified coherent direction of expression changes of miRNAs and their 
predicted functional targets. A. Overlaps of differentially-expressed miRNAs in the three TamR vs. MCF-7/S0.5 cell lines, as 
measured by qPCR assays, are depicted in Venn Euler’s diagrams. Circle size corresponds to the number of altered miRNAs in a given cell 
line. B. Heatmaps depict changes of expression common in all the TamR cells relative to MCF-7/S0.5. Log-fold changes of the miRNAs 
exhibiting altered expression in all resistant cell lines compared to MCF-7/S0.5 (14 upregulated and 8 downregulated) were plotted (panel 
1 of the heatmap). Targets of these miRNAs identified using the inverse correlation analysis exhibited an opposite trend in the direction of 
the altered expression (panel 2), thereby displaying the effect of possible regulation by their miRNAs. C. The predicted functional targets 
of upregulated miRNAs were more downregulated than the non-targets (signed log10 p-values of the Wilcoxon rank-sum test.
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significant inverse correlations (r ≤ -0.8) of expression 
with corresponding regulating miRNAs were obtained for 
each significantly-altered miRNA (Figure 1A). Consistent 
inverse patterns of differential expression were observed 
for miRNAs and their predicted functional targets, 
supporting our hypothesis of miRNA regulation (Figure 
1B, panel I, II and III of the heatmap and Supplementary 
Table 5). For example, predicted functional targets 
(Supplementary Table 6) of miR-135b showed a stronger 
tendency toward upregulation compared to the non-targets 
(p-value < 0.05 for Wilcoxon rank sum test) (Figure 1C).
The significance of miRNA regulation on 
differentially-expressed mRNAs was measured using odds 
ratios (Supplementary Table 7), which indicated that 63% 
of these mRNAs could be accounted for by changes in the 
expression of one or more regulating miRNAs.
We next determined the fraction of miRNAs 
included in the qPCR-based miRNA-mRNA inverse-
correlation analysis that were also identified by small-
RNAseq. Of the total 197 miRNAs included in the inverse-
correlation analysis, 118 showed significant p-values 
(adjusted p-value <0.05) measured by qPCR, and 89 of 
these miRNAs (75%) showed agreement in the direction 
of fold-change by sequencing, whereas 11 miRNAs did 
not agree by small-RNAseq. Eighteen miRNAs (9%) from 
the above set were not detected by small-RNAseq. Thirty-
two of the 79 miRNAs from the 197 miRNA-mRNA 
inverse-correlation list that did not show significant fold-
changes by qPCR exhibited significant fold-change (≥0.7 
log2 fold change) by small-RNAseq, thus adding to the 
overall number of significant miRNA in the miRNA-
mRNA inverse-correlation list.
Figure 3: Inverse-correlation analysis of miRNA and mRNA expression data to identify predicted functional miRNA-
targets. A pairwise correlation matrix for mRNA and miRNA expression levels (Cp values) was constructed from the mean expression 
across cell line replicates. The top ranking miRNA-mRNA pairs by Pearson correlation coefficient (“PCC”, r ≤ -0.8) were selected and 
assessed for a computationally-predicted miRNA-target association inferred by more than one miRNA target predictors. Predicted functional 
targets are the computationally-predicted miRNA-target pairs with high degree of inverse association at expression levels.
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Functional enrichment of miRNA-regulated 
genes
miRNA-regulated mRNAs exhibiting altered 
expression in each of the individual TamR cell lines 
were investigated for their potential to elucidate 
molecular mechanisms through miRNA-mediated post-
transcriptional regulation. miRNAs exhibiting altered 
expression in TamR1 were found to regulate mRNAs 
from cancer-related signaling pathways (FDR < 0.05), 
such as TGF-beta (FDR < 0.05), MAPK, Wnt, EphrinB-
EPHB and ECM-receptor signaling pathways. In TamR4, 
miRNAs exhibiting altered expression seemed to regulate 
mRNAs associated with signaling by Aurora kinases 
(FDR < 0.05), FOXM1 transcription factor network (FDR 
< 0.05), and cell cycle M Phase and G2/M transition 
(FDR < 0.05), glypican pathway, FOXA transcription 
factor network, PDGFR-beta signaling, Kit receptor, axon 
guidance and PDGF signaling pathway. Finally, miRNAs 
exhibiting altered expression in TamR8 were found to 
regulate mRNAs involved in the IFN-gamma pathway, 
Jak-STAT signaling, plasma membrane ER signaling and 
neurotrophin signaling pathways, although the analysis of 
TamR8 did not achieve statistical significance.
We also examined whether these minimally 
overlapping sets of differentially-expressed functional 
targets shared any common mechanisms of drug resistance 
resulting from effects on any specific pathways. miRNA-
regulated mRNAs in TamR1 and TamR4 cell lines showed 
a strong enrichment (FDR< 0.05) of the glypican and 
IGF1 pathways, PDGFR-beta signaling, IFN-gamma 
pathway, plasma membrane ER signaling, TGF-beta 
signaling, nuclear and cytoplasmic SMAD2/3, BMP 
signaling and class I PI3K signaling events. Although 
not significant, association to functional categories for 
miRNA-regulated genes in TamR8 included IFN-gamma 
pathway, Jak-STAT signaling, plasma membrane ER 
signaling and neurotrophin signaling pathways. Thus, 
despite the lack of agreement among resistant cell lines in 
terms of differentially expressed mRNAs, we observed a 
good agreement in terms of affected pathways, implying 
that similar mechanisms of tamoxifen resistance may exist 
in the distinct resistant cell lines.
miRNA-mediated regulation of ESR1 and PGR 
expression
We further examined the involvement of miRNAs 
on two of the key genes in breast cancers, ESR1 and PGR. 
Putative modulators of ESR1 and PGR expression were 
identified by inverse correlation analysis of miRNA and 
mRNA profiles (Figure 4A and Supplementary Table 
5). Such a combinatorial regulation of ESR1 and PGR 
levels is strongly evident in TamR1, where their miRNA 
regulators were expressed at significantly higher levels 
in the tamoxifen-resistant vs. -sensitive cell line; TamR4 
and TamR8 displayed similar patterns, albeit to a lesser 
extent (Figure 4A). Although both up- and downregulated 
miRNA-regulators of ESR1 and PGR were identified, 
higher numbers of the former were observed among 
the regulating miRNAs, suggesting a combinatorial 
downregulation of target mRNAs by upregulated miRNAs 
in TamR cells.
Gene regulation upstream and downstream of 
FOXM1 in TamR4
One of the ER-regulator proteins, Forkhead box 
protein, FOXM1 is known to play an important role 
in ER+ breast cancer by interacting with ESR1. Our 
inverse correlation analysis identified a number of 
significantly upregulated miRNA regulators of this gene, 
consistent with significant downregulation of FOXM1 
in TamR4 (Figure 4B). Expression of the known 
FOXM1-regulated mRNAs, including CHEK2, CCNB1, 
CDK4 and CCND1, as well as miR-135a and let-7f, 
correlated with FOXM1 expression in TamR4, but not 
in TamR1 or TamR8. Moreover, miR-135a was one of 
the consistently downregulated miRNAs in all TamRs, 
with lowest levels of miR-135a observed in TamR4. To 
test whether the reduced miR-135a expression in TamR4 
cells was the direct result of low levels of FOXM1 in 
these cells compared to the tamoxifen-sensitive MCF-7/
S0.5 cells, we performed siRNA knockdown of FOXM1 
and evaluated miR-135a expression. Initially, using 
quantitative real-time RT-PCR analysis, we confirmed 
that FOXM1 showed 3-fold higher expression in MCF-
7/S0.5 vs. TamR4 cells, while miR-135a showed >9 
fold higher expression in MCF-7/S0.5 vs. TamR4 
cells, confirming the findings from the microarray and 
small RNA-seq analysis (Supplementary Figure 1, top 
panel). Although siRNA transfection resulted in over 
80% knockdown of FoxM1 transcript in both cell lines 
(Supplementary Figure 1, top panel), no significant 
alteration of miR-135a expression was observed, 
suggesting that reduction of the FOXM1 level in TamR4 
alone was not sufficient to alter the miR-135a level 
(Supplementary Figure 1, lower panel).
Loss of miRNA regulation for YWHAG and 
YWHAZ
Our inverse correlation analysis also identified 
the two 14-3-3 family members YWHAZ and YWHAG 
upregulated in TamR8 vs. MCF-7/S0.5, but not in TamR1 
and TamR4. These genes appeared to be under direct 
regulation of a relatively small number of miRNAs 
(Figure 4C), including miR-96, miR-942, miR-378, miR-
196a, miR-106b, miR-577, miR-491-5p, which showed 
significant downregulation and inverse correlation with 
the YWHAG and YWHAZ expression in TamR8 (adjusted 
p-value ≤ 0.05).
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Figure 4: miRNA-mediated gene regulation events in tamoxifen-resistant cell lines and functional evaluation of their 
importance in tamoxifen resistance. A. Consistent downregulation of estrogen receptor-alpha and progesterone receptor by several 
miRNAs exhibiting altered expression in TamR1, TamR4 or TamR8 relative to MCF-7/S0.5, as indicated using node colors. B. FOXM1 
expression is regulated by a number of miRNAs in TamR4. Suppressed expression of FOXM1 positively correlated with the expression 
of its transcriptional targets, including miR-135a, let-7f and miR-365. C. YWHAG and YWHAZ appeared to be under miRNA regulation 
in TamR8. Color and intensity of the nodes correspond to the extent of fold-changes observed in the relevant comparison. D. Growth of 
MCF-7/S0.5 and TamR cell lines following treatment with the selective P53-SNAIL binding inhibitor GN25 (3μM) or its solvent, DMSO 
(Control), or E. the selective SKF inhibitor PP2 (2.5 μM) or its solvent, ethanol (Control) in medium with or without tamoxifen (1μM). 
Cells were also treated with combined GN25 and PP2. Cell growth was determined at 72 hrs using a colorimetric assay. F. Expression of 
SNAI2 in MCF7 or TamR cell lines following SNAI2-specific or control siRNA transfection as measured by qRT-PCR. G. Growth of cells 
in tamoxifen-containing medium measured 4 days after siRNA transfection, * p<0.01, ** p<0.001.
Oncotarget57246www.impactjournals.com/oncotarget
Blocking of central miRNA/mRNA tamoxifen 
resistance-related pathways in TamR cells using 
specific chemical inhibitors
Among the miRNAs downregulated in TamR vs. 
MCF7/S0.5 cells were miR-593, miR-342-3p/5p, and 
miR-33b. Among their predicted targets were SNAI2 
(mir-593) and FYN (miR-342-3p/5p and miR-33b), 
respectively, two genes that showed increased expression 
in TamR vs. MCF7/S0.5 cells (Supplementary Figure 
2). To investigate whether the reduced expression of 
miR-593/increased expression of SNAI2 had functional 
significance for tamoxifen resistance, we evaluated the 
growth of TamR and MCF7/S0.5 cells in the presence 
or absence of tamoxifen when the SNAIL-P53 binding 
inhibitor GN25 was added. The results showed that GN25 
alone has a moderate effect on TamR cells but, when 
combined with tamoxifen, dramatically reduces growth, 
suggesting that inhibition of SNAI2 activity renders TamR 
cells highly susceptible to tamoxifen (Figure 4D).
Similarly, we evaluated whether the reduced 
expression of miR-342-3p/5p and miR-33b/increased 
expression of FYN had functional significance for 
tamoxifen resistance by evaluating the growth of TamR 
and MCF7/S0.5 cells in the presence or absence of 
tamoxifen when the cells were treated with SRC family 
kinase inhibitor PP2. The results showed that, treatment 
of TamR cells with PP2 resulted in significant growth 
inhibition of TamR cells, but no marked effect on the 
parental cell line (Figure 4E). Interestingly, similar to our 
observation with SNAI2 inhibitor, PP2 markedly enhanced 
tamoxifen-induced growth inhibition in cells otherwise 
resistant to tamoxifen. Moreover, to evaluate whether the 
2 genes promote tamoxifen resistance independently or in 
combination, we treated TamR cells with the combination 
of PP2 and GN25 and found that the combination resulted 
in much more potent inhibition than the 2 compounds 
used separately (Figure 4D and 4E), suggesting that the 2 
genes may promote resistance through separate pathways. 
In the tamoxifen-sensitive parental cell line, treatment 
with GN25, tamoxifen or combination of the 2 led to 
comparable and dramatic growth inhibition (Figure 4D), 
while PP2 treatment did not affect the growth of parental 
cell lines (Figure 4E).
siRNA-mediated knockdown of SNAI2 increases 
tamoxifen-induced growth inhibition in 
tamoxifen-resistant breast cancer cell lines
To further evaluate whether the reduced expression 
of mir-593 and corresponding increased expression of its 
target gene SNAI2 is associated with tamoxifen resistance, 
we performed gene knockdown of, SNAI2. The result 
showed that siRNA transfection of breast cancer cell 
lines led to over 80% reduction in SNAI2 expression 
as measured by qRT-PCR (Figure 4F). The reduction 
in SNAI2 resulted in significant reduction of TamR 
cell growth, while no significant reduction in growth of 
parental MCF7/S0.5 cells was observed (Figure 4G), 
suggesting that mir-593 may affect tamoxifen resistance 
by controlling SNA12 expression.
miRNA alterations in the cell line model are 
also seen in breast cancers of patients receiving 
adjuvant tamoxifen monotherapy
We assessed the clinical relevance of our results 
from the cell line model by comparing the miRNA 
data therefrom with those of primary tumors from ER+ 
breast cancer patients receiving adjuvant tamoxifen 
monotherapy. In this recent study, global miRNA 
expression in primary tumors of patients who experienced 
disease recurrence despite tamoxifen treatment were 
compared those who did not (data set GSE37405) [19]. As 
outlined in Materials and Methods, the miRNA data from 
the clinical study consisted of three independent cohorts. 
Patient classification was designed to separate training 
performance and independent test performance for all of 
the single miRNAs and for combinations of miRNAs by 
fitting a classifier on each cohort independently and testing 
that classifier on all three cohorts. Prediction performance 
was assessed by ROC analysis and summarized by the 
area under the ROC curve (AUC). The analysis showed 
that as single miRNA classifiers, miR-190b, miR-29b 
miR-516a-5p and miR-203, were the most promising 
(Supplementary Figure 3). Improved prognostic power of 
treatment outcome was observed for the combination of 2 
miRNAs (miR-190b and miR-516a-5p) in 2 of 3 patient 
cohorts (Figure 5). Other combinations, including the 2 
miRNAs combinations: miR-190b and miR-29b, miR-
190b and miR-516a-5p, and the 3 miRNAs combinations: 
miR-190b, miR-29b and miR-203; miR-29b, miR-516a-
5p and miR-203; miR-190b, miR-516a-5p and miR-29b, 
miR-190b, miR-516a-5p and miR-203 also exhibited 
promising prognostic power of treatment outcome 
(Supplementary Figure 3).
DISCUSSION
Drug resistance is a major clinical issue in 
cancer treatment. In this study, we identified molecular 
mechanisms of tamoxifen resistance in ER+ breast cancer 
affected by miRNAs and their target mRNAs in a cell 
line model. To strengthen the regulatory associations 
of miRNAs and target mRNAs, we utilized inverse 
expression correlations between miRNAs and their 
computationally-identified mRNA targets and integrated 
curated evidence of TF-DNA and protein-protein 
interaction information to identify relevant miRNA-
mediated mRNA regulations. Several miRNA-target 
relationships that extend beyond the known signaling 
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events associated with tamoxifen resistance in breast 
cancer were identified.
Genomic heterogeneity is an important factor 
that complicates the interpretation of results obtained 
by global analysis of patient tumor material using 
advanced genomic technologies. This includes evaluation 
of tamoxifen resistance, which may be the result of 
different mechanisms in different patient tumors as 
well as within different areas of a single tumor [20]. 
Single cell sequencing may overcome this problem, 
but this technique is not commonly available and thus 
intratumor heterogeneity and thereby heterogeneity in 
the resistance mechanisms significantly complicate data 
interpretation [20]. Previous studies have shown that 
the TamR cell line model analyzed in the present study 
displays protein alterations also observed in clinical 
samples of patients resistant to tamoxifen treatment [21, 
22], supporting the clinical relevance of the model. The 
three individual tamoxifen-resistant cell lines studied 
may represent individual resistant cell clones within a 
tumor. In accordance with this, we observed that the 
distinct TamR cell lines exhibited both shared and unique 
miRNA and mRNA expression changes. However, despite 
the uniqueness of miRNAs and mRNAs affected in the 
individual resistant clones, there was a good overall 
agreement in the affected molecular pathways.
Adding clinical relevance to our findings, 
comparison of the miRNA alterations observed in the 
cell line model to those observed in a large cohort of 152 
primary ER+ breast cancer patients treated with tamoxifen 
[19] showed that in particular the combination of 2 
miRNAs (miR-190b and miR-516a-5p) were predictive 
of treatment outcome in 2 of 3 patient cohorts.
We found that more than 60% of the significantly 
differentially-expressed genes showed a coherent 
inverse correlation of expression to their putative 
miRNA regulators (Supplementary Table 7). In addition, 
combinatorial regulation by miRNA, where more than 
one miRNA targets the 3’ UTR of mRNAs, may lead to 
a stable attenuation of expression of target mRNAs [23]. 
As an example of combinatorial regulation by miRNA 
is 14-3-3γ (YWHAG), which frequent overexpression is 
predictive of poor patient outcome in tamoxifen-resistant 
breast cancer and functions by activation of the MAPK 
and PIK pathways [24, 25]. We observed that YWHAG 
and YWHAZ were upregulated in TamR8, but not in 
TamR1 or TamR4. Their putative miRNA regulators 
were significantly downregulated in TamR8 (p ≤ 0.05). 
Bergamaschi et al. [24] recently showed that tamoxifen 
plays a suppressive role on expression of miR-451 
in TamR cell lines by inducing loss-of-regulation of 
YWHAZ due to downregulation of miR-451, its known 
regulatory miRNA. However, we found no significant 
over-expression of miR-451 in our study.
Furthermore, regulatory circuits consisting of 
transcription factors and miRNAs regulate gene expression 
at both the transcriptional and post-transcriptional levels. 
Transcription factor FOXM1, previously shown to bind the 
promoter of miR-135a and to positively regulate miR-135a 
levels [26], showed a downregulation, in agreement with 
reduced level of miR-135a and increased expression of 
EPHA4/EPHA7 specifically in TamR4 (Figure 4B). Given 
Figure 5: ROC curve analysis to assess the ability of miRNAs to predict outcome of cohorts of ER+ breast cancer 
patients receiving tamoxifen monotherapy. Selected miRNAs that exhibited altered expression in TamRs vs. MCF-7/S0.5 cell lines 
were also predictive of recurrence following tamoxifen treatment. The 2-miR classifier, miR-190b and miR-516a-5p, was fit on cohorts 1 
and 2 (Fit cohort) and then applied to both cohorts independently. Training performance is observed when Fit cohort and test cohorts are 
the same (dotted lines), while independent test set performance is observed when they differ (solid lines).
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the important roles of FOXM1, EPHA4 and EPHA7 on 
breast cancer outcome [27-29], FOXM1 and miR-135a 
were good candidates for a siRNA knockdown study. 
However, we found that reduction of FOXM1 alone was 
not sufficient to modulate miR-135a expression in TamR4, 
and downregulation of miR-135a was dependent on other 
factors that were not modulated in this siRNA study.
In our experiment, miR-181b was consistently 
upregulated in all tamoxifen-resistant cell lines. In 
agreement with this, increased miR-181b expression 
was also associated with tamoxifen resistance by others 
[17]. Functional targets of miR-181b appeared to be 
relevant for breast cancer and drug resistance and were 
significantly downregulated in our study, including 
HEY1, CA2, PIK3R1, LYN, ESR1, JUN, STAT1, MYB, 
BCL2, CYCS, BAMBI, CTGF and SOX9. MiR-342 was 
one of the consistently downregulated miRNAs in all 
resistant cell lines and has been linked with tamoxifen 
resistance by Cittelly et al. [30] We identified 14 predicted 
functional targets of miR-342-3p/5p, including FYN, 
TGFBR1, COL4A6, CDKN1A, and Ephrins EPHA4/7 
(Supplementary Figure 2). miR-221 and miR-222 are 
known to be associated with tamoxifen-resistance [14], 
and our data provided some support for this hypothesis. 
miR-221 level was slightly increased in TamR1 and 
TamR4 (log2FC 0.53 and 0.64, respectively, p ≤ 0.05), 
but not in TamR8, whereas miR-222 was downregulated 
specifically in TamR4 (log2FC -0.51, p ≤ 0.05), perhaps 
as a consequence of a regulatory event upstream of miR-
221/222 regulation.
The miRNA-mRNA inverse-correlation analysis 
identified miR-593, which was downregulated in TamR 
cell lines vs. MCF7/S0.5, while its predicted target 
SNAI2 was upregulated. Similarly, miR-342-3p/5p and 
miR-33b were downregulated in TamR vs. MCF7/S0.5 
cells, while their predicted target FYN was upregulated. 
To assess whether the two miRNA-gene axis were central 
to the tamoxifen resistance phenotype, we used chemical 
inhibitors of the two genes and evaluated their influence 
on TamR growth. Interestingly, GN25, a chemical agent 
interfering with SNAI2 binding to P53, reduced the 
growth of all three TamR cell lines only in the presence of 
tamoxifen, while no effect was observed on TamR growth 
in the absence of tamoxifen, and its effect on the parental 
cell line was independent of tamoxifen. This suggests that 
the reduced mir-593/enhanced SNAI2 expression observed 
in TamR cells may influence the effect of tamoxifen, and 
that specific inhibition of SNAI2 function may render 
the cells susceptible to the growth-inhibiting effects of 
tamoxifen. Some GN25-mediated growth inhibition of 
the parental cell line was also observed. While SNAI2 
was upregulated in TamR vs. parental cell lines, some 
expression in the parental cell line was observed. As GN25 
treatment may lead to the complete abolition of SNAIL 
activity, and since SNAI2 is an anti-apoptotic molecule 
[31], complete abolition of its activity may affect survival 
of the cells, including the parental cell lines. This suggests 
that while residual expression of SNAI2 is essential 
for cell survival, the increased expression observed in 
tamoxifen-resistant cells may contribute to the resistance 
phenotype.
Similarly, we performed growth assays of TamR 
cell lines in the presence of a selective inhibitor of SRC 
family kinases PP2 and showed that the inhibitor reduced 
the growth of TamR cells, but had no significant effect 
on the tamoxifen-sensitive parental cell line, suggesting 
that the altered miR-342-3p/5p and miR-33b/FYN axis 
observed in TamR cells is important in the resistance 
mechanism. TamR cell growth was inhibited both in 
the presence and absence of tamoxifen, suggesting that 
FYN acts independently of ER. In line with this, we 
have recently shown that siRNA knockdown of FYN in 
TamR cells enhanced their susceptibility to the effects 
of tamoxifen [32]. Although we have not proven that the 
PP2-mediated growth inhibition of TamR cells was due 
to inhibition of FYN kinase activity, as the drug targets 
multiple SRC family kinases at high concentrations, 
it seems highly plausible since FYN and LYN were 
the only SRC family kinases that exhibited increased 
expression, and knockdown of LYN in TamR cells 
did not affect cell growth [32]. Similarly for GN25, 
only SNAI2 was upregulated in TamR, and not the 
other snail proteins, SNAI1 or SNAI3, recognized by 
GN25. Moreover, using the PP2 and GN25 inhibitors in 
combination led to a dramatic reduction in cell viability 
beyond that of either of the two compounds alone, 
suggesting that the two genes independently contribute 
to resistance. It may be argued that chemical inhibitors 
are non-specific and the effect may not be attributed to 
a specific gene, however, knockdown of SNAI2 using 
siRNA transfection resulted in marked reduction in 
cell growth in TamR cell lines similar to the chemical 
inhibitors, confirming the importance of the genes in 
endocrine resistance. In agreement with this, a recent 
report showed that reduced expression of SNAI2 reduces 
the aggressiveness of cancer cells [33].
A recent study by Ward et al. [34] identified miR-
375 as a marker of tamoxifen resistance in a different 
tamoxifen-resistant cell line model, showing that miR-375 
expression level was directly proportional to tamoxifen 
sensitivity. However, in our study, we observed no 
miR-375 downregulation and indeed found a significant 
upregulation in TamR8 (logFold change 1.05, p ≤0.05), 
perhaps due to differences in the cell models used. Further, 
of the ten miRNAs with significant downregulation in the 
tamoxifen-resistance models of Ward et al. [34], three 
were also downregulated in our study (miR-135a, miR-
135b, miR-190b), while five were missing or undetectable 
by our qPCR assays. Among twelve significantly 
upregulated miRNAs in the same study [34], five were 
also upregulated in our study in one or more cell lines 
(miR-551b, miR-519a, miR-521, miR-205 and miR-455-
3p), while four were missing or undetectable by our qPCR 
assays.
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Our systematic approach of inferring miRNA-
target relationships elucidated important and detailed 
gene regulation events that may contribute to the 
development of tamoxifen resistance. Several miRNA-
target relationships were identified, many showing 
significant association with various signaling events 
previously associated with the development of tamoxifen 
resistance. Clearly further functional studies are needed 
to experimentally confirm the identified miRNA-target 
relationships. While we realize that the observed gene 
regulation is a combination of miRNA targeting as well 
as post-transcriptional modifications of the upstream 
promoters of miRNAs and/or their target genes, our study 
nonetheless supports the importance of miRNA-mediated 
gene regulatory events in tamoxifen resistance. Targeted 
experiments based on our findings will bring insight into 
tamoxifen resistance in ER+ breast cancer and provide the 
basis for future medical intervention of ER+ tamoxifen-
resistant breast cancer.
MATERIALS AND METHODS
Cell lines and standard culture conditions
The human breast cancer cell line MCF-7 was 
originally received from The Breast Cancer Task Force 
Cell Culture Bank, Mason Research Institute (Worcester, 
MA). The MCF-7 cells were gradually adapted to grow 
in low serum concentration and the tamoxifen-sensitive 
subline MCF-7/S0.5 [35] was used to establish TamR cell 
lines by extended treatment with high dose tamoxifen (1 
μM), as previously described [21, 36]. The three TamR 
cell lines, MCF-7/TamR-1 (TamR1), MCF-7/TamR-4 
(TamR4), and MCF-7/TamR-8 (TamR8) were derived 
from distinct colonies grown in culture of MCF-7/S0.5 
cells incubated with tamoxifen [22]. The cells were grown 
in a standard phenol-red-free DMEM:F12 (1:1) medium 
(21041-025, Gibco, Naerum, Denmark) supplied with 1% 
heat-inactivated FBS (10270-106, Gibco), 6 ng/ml insulin 
(I6634, Sigma, St Louis, MO, USA) and 2.5 mM glutamax 
(35050, Gibco). The standard medium for the TamR cell 
lines was supplied with 1 μM tamoxifen (T5648, Sigma). 
MCF-7/S0.5 and the TamR cell lines were passaged once 
per week and seeded in 1x105 and 1.4x105/T25 flasks, 
respectively. The cell lines were cultured at 37°C and 
5% CO2 and kept at low passage numbers throughout 
the experiments (<10 passages). For authentication of 
the cell lines DNA fingerprinting by short tandem repeat 
(STR) analysis (Cell IDTM system, Promega, Roskilde, 
Denmark) was performed.
miRNA profiling using quantitative real-time 
PCR
Total RNA from cell line cultures was extracted and 
purified using TRIzol (Invitrogen, Naerum, Denmark) 
and EtOH-precipitated. miRNA qPCR profiling was 
conducted using miRCURY LNA™ Universal RT 
microRNA PCR system (Exiqon, Vedbaek, Denmark), 
per manufacturer’s instructions. In brief, 50 ng total RNA 
was reverse-transcribed in 40 μl reactions on a Bio-RAD 
S1000 Thermal Cycler (60 min at 42°C, followed by heat-
inactivation of the reverse transcriptase for 5 min at 95°C). 
From the resulting cDNA, 32.5 μl was used for a SYBR 
green master mix and run in 10 μl real-time amplification 
on microRNA Ready-to-use PCR, Human panel I+II, 
V2.R plates (Exiqon, product number 203608) on a Roche 
LightCycler® 480 real-time PCR system. The applied PCR 
settings were: 10 min at 95°C, 40 amplification cycles 
(95°C/10 sec, 60°C/1 min, ramp rate 1.6°C/sec). For each 
cell line, three biological replicates were analyzed.
Small RNA library and sequencing
Total RNA (48 μl) from cell line cultures was 
extracted and purified using a TRIzol reagent kit 
(Invitrogen) according to the operational manual 
protocol. Small RNA libraries were generated from the 
purified RNA using Illumina's Small RNA v1.5 Sample 
Preparation kit (Illumina, Shanghai, China) according to 
the manufacturer’s guidelines. Briefly, the RNA sample 
was size fractionated, and 18-30 nt RNA was isolated 
and purified (6-8 μl). After 5' and 3' adaptor ligation, 
RNA was reverse-transcribed and amplified using 14 
PCR cycles of 98°C for 10 sec and 72°C for 15 sec to 
generate small RNA libraries. The libraries (1 μl) were 
loaded on an Agilent Technologies 2100 Bioanalyzer to 
check size and purity, and qPCR to check concentration. 
Libraries were sequenced on an Illumina Genome 
Analyzer II and processed with the Illumina pipeline 
v1.4.0.
Accession numbers
NCBI Gene Expression Omnibus database accession 
number for the raw data of miRNA qPCR and miRNA 
sequencing of MCF-7/S0.5 and the three TAMR cell lines 
is GSE56411.
Gene expression arrays
Total RNA was purified from each cell line using 
TRIzol (Invitrogen) and EtOH-precipitated. Two to 3 
independent cultures were used for RNA purifications for 
each of the TamR cell lines grown separately, and each 
of the biological replicates (3, 3 and 2, respectively) were 
individually analyzed on Affymetrix Gene Chip® Human 
Genome U133 plus 2 arrays (High Wycombe, UK). For 
MCF-7/S0.5 cells, RNA from 6 independent cultures were 
purified and arrayed separately. One cycle target labeling 
and hybridization were performed following manufacturer’s 
instructions and as described by Elias et al. [32].
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Analysis of miRNA qPCR data
Primers leading to more than one peak in melting 
characteristics were identified and annotated via melting 
curve analysis performed in R. We applied a signal-
dependent, non-linear, normalization method similar to 
that described by Workman et al. [37]. The offset amounts 
were calculated by fitting cubic-spline to the entire 
dataset and were added to the raw data to obtain desired 
target distributions. Our normalization approach offered 
20% reduction in replicate standard error of means. 
Subsequently, we used limma [38] from Bioconductor 
package to identify miRNAs with altered expression 
between tamoxifen-resistant and -sensitive cell lines.
Analysis of sequencing data
Low-quality 3’ ends of reads were trimmed, 
and those shorter than 15 nt were eliminated. Prior to 
alignment, a table was compiled of unique reads with the 
number of copies of each in a given experiment. These 
reads were aligned to the subset of mature human miRNA 
sequences obtained from miRBase [39] September 2010 
release, that were covered by the qPCR panels. BLAT 
search of reads to the reference was applied with no 
mismatches or gaps allowed in the alignment. Multiple-
mapped reads were discarded from further analysis. 
Normalized read counts per miRNA were analyzed for 
differential expression using DESeq [40] in Bioconductor 
R environment.
Analysis of microarray data
Raw gene expression data was obtained from 
Elias et al. [32]. Our inverse correlation analysis to infer 
predicted functional miRNA-target relationships is highly 
dependent on the gene expression patterns, and technical 
variances were minimized by processing the arrays using 
the RMA (robust multi-array average) approach [41] 
implemented in the Bioconductor package affy [42]. 
RMA normalization consisted of three steps: background 
correction, probe-level quantile-normalization and 
probeset summarization using a robust linear model fit to 
the log-transformed normalized values. Genes exhibiting 
altered expression were identified using limma package 
[38] in R.
Integration of miRNA-mRNA expression data
qPCR-measured miRNAs exhibiting higher absolute 
fold-changes (absolute log2 fold-change ≥0.7, no p-value 
threshold) in one or more TamR vs. MCF-7/S0.5 cell 
lines were selected. To cover a larger and unbiased set 
of predicted miRNA-target relationships, we considered 
target predictions made by the following tools: miRanda, 
miRDB, miRWalk, PICTAR5, RNA22 and Targetscan [43-
48]. We next calculated Pearson’s correlation coefficient, 
r for expression levels of each predicted miRNA-target 
pairs. Due to the differences in the sample sizes of relevant 
cell lines in miRNA and mRNA expression datasets, RMA 
normalized expression levels of each gene and Cp-values 
for every miRNA were summarized to one value per cell 
line type by calculating an average across replicates. 
Since miRNA expression is expected to be inversely 
proportional to their mRNA targets and Cp-values from 
qPCR are inversely proportional to expression levels, 
a series of tests for correlations between Cp and RMA 
values were performed over the summarized expression 
datasets and the resulting correlation coefficients were 
negated. Highly negatively-correlated (r ≤ -0.8) miRNA-
mRNA pairs were inferred to have a predicted functional 
interaction if at least two of the six target predictors 
supported the interaction.
To assess our hypothesis that the relative extent of 
changes in expression of the predicted functional targets 
is higher than that of the non-targets, sets of correlated 
miRNA-mRNA pairs were tested by two-sample Wilcoxon 
rank-sum tests for each resistant cell line. Two-sided 
Wilcoxon tests were performed on the observed fold-
changes of predicted functional miRNA targets versus 
fold-changes of non-targeted mRNAs, including the 
predicted, but not functional, target mRNAs. P-values of 
Wilcoxon tests were corrected for multiple testing errors 
via the Benjamini Hochberg method. If the target mRNAs 
had lower ranks than the background list of mRNAs, then 
the log10 of Wilcoxon rank sum test p-values were given a 
negative sign. This analysis was carried out in R statistical 
environment.
Identification of tamoxifen resistance-associated 
miRNAs in tumors of tamoxifen-treated breast 
cancer patients
The miRNA expression profiles of the cell lines 
were compared with our previously published dataset 
(GSE37405) [19] of global miRNA profiles of primary 
ER+ tumor samples from 152 adjuvant tamoxifen-treated 
breast cancer patients. This study was comprised of three 
cohorts, test sets 1, 2 and 3. Test set 1 is a cohort of 52 
patients who received an average of 2 years of tamoxifen 
therapy, had large tumors (12-95 mm) and an average 
>4.5 axillary lymph nodes with tumor infiltration at the 
time of diagnosis. Of these patients, 26 later experienced 
recurrence. Test set 2 consisted of 60 patients with high 
numbers of tumor-infiltrated lymph nodes (range: 1-29, 
average: 8.6), 30 of whom experienced recurrence. Test 
set 3 consisted of 40 patients who had received 3-5 
years of tamoxifen therapy, and of these 19 experienced 
recurrences. Clinical and pathological characteristics of 
the three patient subgroups are listed in Supplementary 
Table 8. Normalization and pre-processing of microarray 
data from GSE37405 [19] was performed in R using 
limma package [38]. The resistant cell lines, TamR1, 
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TamR4 and TamR8, were considered model systems 
for recurrence, and the parental cell line MCF-7/S0.5 
was considered a model for patients without recurrence. 
Differentially-expressed miRNAs from the cell line 
model were assessed for possible changes of expression 
between recurrent and non-recurrent patient samples in 
the three test sets (cohorts) fitting a logistic regression 
model. miR-190b, miR-29b, miR-516a-5p, miR-203, 
expression profiles were used to calculate their predictive 
power to differentiate recurrent or non-recurrent samples 
in GSE37405 as a single marker or in combinations. Area 
under the curve (AUC) values were calculated using the 
ROCR package [49].
Gene knockdown studies
Small interfering RNAs (siRNAs) targeting 
SNAI2, FOXM1 and scrambled siRNA controls were 
designed and synthesized by Qiagen (Copenhagen, 
Denmark). Cell transfection was performed using the 
Ingenio electroporation kit according to manufacturer’s 
instructions (Mirus, Madison, WI, USA). Briefly, cells 
grown to 70-80% confluence were harvested, counted and 
resuspended in 100μl of Ingenio electroporation solution 
containing 150 nM of the required siRNAs. The mixture 
was transferred into a 0.2 cm cuvette and electroporated 
using an Amaxa nucleofector device (Lonza, Cologne, 
Germany). Transfected cells were then seeded in the 
appropriate culture medium. Cells were harvested 48 or 
72 hours later for evaluation of the efficiency of gene 
knockdown using real time PCR and/or Western blotting 
[50]. Growth assay was performed 96 hours after gene 
knockdown. Scrambled siRNA transfected cells were used 
as controls.
Evaluation of the effect of specific chemical 
inhibitors on TamR cell growth
MCF-7/S0.5 and TamR cell lines (105cells/ml) 
were seeded in 24-well plates (Sigma) in the presence or 
absence of 1μM tamoxifen (Sigma) and 3μM SNAIL-P53 
binding inhibitor GN25 (Millipore, Darmstadt, Germany) 
or 2.5μM SRC family kinase inhibitor PP2 (Tocris 
Bioscience, Bristol, UK). Cell growth was measured 3 
days after seeding using a crystal violet-based colorimetric 
assay. Each assay was performed in quadruplicates.
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